CL — Colgate-Palmolive Company

As of 2026-09-13 the tape was clearly skeptical: CL was down 2.22% on the week, 5.98% on the month, 2.96% over three months and 2.30% over six months, with RSI at 33.39 and price 3.69%, 5.11% and 1.24% below its 20-, 50- and 200-day averages. Sell-side is split rather than hostile - 18 buys against 25 holds and 2 sells (consensus 'Hold'), with a $97.78 consensus price target and a $102.60 recent-average target implying meaningful upside, and the research brief notes upgrades on improving organic volume. What the market is discounting is the GAAP earnings picture (Q2 2026 EPS of $0.86 versus $0.91 a year earlier; a -$37M net loss in Q4 2025), organic growth of only 2.4% in Q2 2026, the exploratory Softsoap/Irish Spring/Speed Stick divestiture, and book equity of just $236M. Net: a defensive name people hold for the 2.28% yield and 0.32 beta, not one they are adding to right now.

Revenue has genuinely reaccelerated off a flat 2024. Sequential quarterly revenue rose six straight quarters from $4,911M (Q1 2025) to $5,110M, $5,131M, $5,230M, $5,324M and $5,361M (Q2 2026), and YoY growth flipped from -3.0% in Q1 2025 to +1.0%, +1.9%, +5.8%, +8.4% and +4.9% in Q2 2026. Important caveat: the brief shows Q2 2026 organic sales of only +2.4% against +4.9% reported net sales, so roughly half the headline acceleration is FX/portfolio rather than underlying volume - this is a modest reacceleration, not a boom. Gross margin is expanding (Q2 2026 61.5% versus 60.1% a year earlier), but GAAP operating margin has compressed (18.9% in Q2 2026 versus 21.1% in Q2 2025) and GAAP diluted EPS has now fallen three straight reported quarters (-$0.046 in Q4 2025, $0.80 in Q1 2026, $0.86 in Q2 2026 versus $0.90/$0.85/$0.91). That decline looks charge-driven, not demand-driven: the brief notes Q2 2026 base-business EPS rose 8% to $0.99. Cash flow is the cleanest signal and it is accelerating - trailing-twelve-month free cash flow of $3,858M is up roughly 14.5% versus the prior TTM's $3,370M, with Q2 2026 FCF of $867M up from $776M. Verdict: modest top-line inflection, expanding gross margin, GAAP earnings distorted downward by one-offs, and free cash flow growing at a low-teens rate.

Fairly valued on forward cash earnings, expensive only on distorted trailing GAAP. As of 2026-09-13 the $86.80 price was 34.1x trailing EPS of $2.557 - above the stock's own five-year average trailing P/E of 30.94x - but that trailing EPS absorbs the Q4 2025 GAAP loss and other charges. On next-FY consensus EPS of $3.867 the forward P/E is 22.4x, and on TTM free cash flow of $3,858M (about $4.82 per share on ~800M shares) the FCF yield is 5.6%. Price/sales of 3.30x sits below the five-year average of 3.61x. PEG of -1.17 and price/book of 293x are artifacts of depressed GAAP earnings and a buyback-shrunk equity base, and should be ignored. For a 60%-gross-margin, roughly 30% ROIC staples franchise growing base-business EPS around 8% with a 2.28% dividend, 22x forward earnings is roughly market-appropriate and toward the lower end of CL's own historical range - not a bargain, not a bubble.

The multiple is pricing in mid-single-digit growth rather than a turnaround, and the GAAP headline is understating the business. Trailing EPS of $2.557 makes the P/E look like 34x, while next-FY consensus of $3.867 implies EPS rising roughly 51% - almost all of that is the roll-off of charges rather than new profit, and Q2 2026 base-business EPS of $0.99 versus GAAP $0.86 shows the size of the gap. If those charges fade, the same $86.80 price would sit on about 22x earnings with a 5.6% FCF yield and the stock would screen cheap on a 2027 basis. The opposite risk is that reported growth of 4.9% is running roughly double organic growth of 2.4% - if FX reverses, reported growth converges on 2-3% and the multiple has no reason to re-rate. Watch two things: whether organic volume clears management's stated >3% target, and whether the GAAP-to-base EPS gap actually closes rather than recurring every quarter.

Weak momentum, near-oversold, no confirmation of a low. As of 2026-09-13, RSI(14) was 33.39 - near oversold but not extreme - with price 3.69% below the 20-day, 5.11% below the 50-day and 1.24% below the 200-day average, implying roughly $90.1, $91.5 and $87.9 respectively. Returns were negative on every measured horizon (-2.22% one week, -5.98% one month, -2.96% three months, -2.30% six months) and the stock sat essentially at the midpoint of its 52-week range. That is a mild downtrend inside a wide range, not an oversold washout with a reversal signal. Implication for entry timing: there is no urgency to buy; RSI in the low 30s for a defensive name often stabilizes, but confirmation would require reclaiming the 200-day near $88 and then the 50-day near $91.5. A patient buyer would scale in on weakness toward the high-$70s/low-$80s or wait for a moving-average reclaim rather than chase a bounce.

• Defensive-sector rotation: with macro uncertainty elevated, capital has favored staples with inelastic daily demand, and CL's 0.32 beta makes it a safe-haven holding - but that same low beta means it lags badly if risk appetite returns.
• FX and emerging-market exposure: more than 40% of volume is in emerging markets, and Q2 2026 reported net sales growth of 4.9% versus organic growth of 2.4% means currency translation did roughly half the work - a firmer dollar would quickly shrink headline growth.
• Input cost, energy and freight volatility: gross margin reached 61.5% in Q2 2026, and holding that level depends on productivity-program savings offsetting commodity and logistics swings.
• Rate competition for yield: a 2.28% dividend yield sits well below the risk-free rate, so total return depends on EPS and FCF growth; higher-for-longer rates cap staples multiples across the group.
• Private label and value-seeking consumers: the brief flags a 0.4% drag from lower private-label pet food sales, and mass-market personal care is exactly where private label bites - which is why those brands are the ones being considered for divestiture.

• Potential divestiture of Softsoap, Irish Spring and Speed Stick (Goldman Sachs process reportedly under exploration as of September 2026, potentially $1B+): a sale would sharpen the mix toward higher-margin Oral Care and Hill's Pet Nutrition and could fund buybacks or a special dividend.
• Q3 2026 earnings, expected late October 2026: the two numbers that matter are organic volume growth against management's >3% target and whether the GAAP-to-base-business EPS gap closes.
• Continued free cash flow growth and the next dividend declaration: TTM FCF of $3,858M is up roughly 14.5% YoY, and the $0.53 quarterly dividend consumes only about 44% of it.
• A rate-cut cycle or a growth scare that pushes capital further into defensives would re-rate the whole staples group, CL included.

• Organic growth stuck near 2.4%: if pricing power fades and volume does not take over, reported growth converges toward 2% and a 22x forward multiple has little to support it.
• 'One-off' charges that keep recurring: a Q4 2025 GAAP net loss of -$37M and three straight quarters of YoY GAAP EPS declines mean trailing EPS of $2.557 can stay depressed, keeping the headline P/E near 34x.
• Almost no equity cushion: stockholders' equity of $236M, debt-to-equity of 33.3x, current ratio of 1.026 and quick ratio of 0.671 - buyback-driven rather than distress, but it removes book-value support and limits balance-sheet flexibility.
• FX reversal: with translation contributing roughly half of Q2 2026's 4.9% reported growth, a stronger dollar would erase much of the apparent acceleration.
• Private-label and value trade-down in Personal Care and Home Care, precisely the segments being considered for divestiture, plus the execution risk of a $1B+ brand sale and the stranded costs it could leave behind.
• Thin valuation cushion: 34.1x trailing earnings versus a five-year average of 30.94x leaves little room for a growth or margin disappointment.

Not broken, but not cheap enough to compensate for its limits. At $86.80 as of 2026-09-13 you are paying 22.4x next-FY EPS and a 5.6% free-cash-flow yield for roughly 2-3% organic growth, about 8% base-business EPS growth, a 2.28% dividend and a 60%-gross-margin, roughly 30% ROIC franchise with a 0.32 beta. The GAAP figures look worse than the business (charges) and the technicals look worse than the fundamentals, so this is not a deteriorating company - but a 34x trailing multiple, a nearly equity-less balance sheet and sub-3% organic growth leave no margin of safety. Better entries exist lower, or after organic growth clears 3% and the charges stop recurring.

Blended two methods as of 2026-09-13: (1) a 24x justified forward P/E - a modest premium for a 60%+ gross-margin, ~30% ROIC staples franchise with ~8% base-business EPS growth, but below its 5-year 30.94x trailing average - applied to the $3.867 next-FY consensus EPS gives $92.81; (2) a 5.1% required FCF yield applied to TTM free cash flow per share of $4.82 ($3,858M FCF / ~800M shares) gives $94.53. Averaging the two produces $93.67, rounded to $93.70 - about 8% above the $86.80 price and below the $97.78 sell-side consensus, reflecting that GAAP earnings are distorted today but organic growth is only mid-single-digit.